Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

NCT02887248 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Enrollment issues

Conditions

Urothelial Carcinoma
Bladder Cancer
Transitional Cell Carcinoma

Interventions

DRUG: nab-paclitaxel
DRUG: Gemcitabine

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]